Product Details

Verclox-S Oral Suspension meets pharmacopoeial standards for the treatment of bacterial infections in children and patients who have difficulty swallowing capsules. Specifically, each 5ml delivers Cloxacillin Sodium IP equivalent to 250mg Cloxacillin, in a flavoured base. As a result, it offers targeted antibacterial coverage against penicillinase-producing staphylococcal strains in a convenient liquid formulation.

The suspension contains:

• Cloxacillin Sodium IP (equivalent to Cloxacillin 250mg per 5ml, in a flavoured base) – A penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis. Consequently, it remains effective against Staphylococcus strains that produce beta-lactamase enzymes capable of inactivating standard penicillins.

Physicians prescribe Verclox-S for the treatment of infections caused by penicillinase-producing staphylococci, including skin and soft tissue infections, in children and patients requiring a liquid formulation. In addition, its oral suspension format supports accurate paediatric dosing and easier administration than capsules. Because of this profile, Verclox-S suits paediatric practices, general practice, and hospital settings managing resistant staphylococcal infections.

Key Features:

• Overall, this formulation guarantees pharmaceutical-grade purity
• Additionally, the oral suspension format supports accurate paediatric dosing
• Furthermore, each 5ml delivers precise, validated dosage accuracy at 250mg
• Notably, rigorous quality testing backs every stage of manufacturing
• Beyond that, amber bottle packaging protects the light-sensitive formulation
• Ultimately, a reliable supply chain suits bulk distribution to hospitals, clinics, and pharmacies